腹水浓缩回输治疗失代偿期肝硬化患者肾血流和血清血管活性因子水平的变化

doi:10.3969/j.issn.1672-5069.2020.05.026

摘要/Abstract

摘要： 目的研究腹水浓缩回输治疗失代偿期肝硬化患者疗效及对肾血流和血清血管活性因子的影响。方法 2016年5月～2018年5月收治的102例失代偿期肝硬化患者,其中60例接受腹水浓缩回输治疗,42例接受常规治疗,观察2 w。使用超声检测肾主动脉(MRA)、叶间动脉(IRA)和段动脉(SRA)收缩期最大血流速度和舒张期最低血流速度,检测血清内毒素(LPS)、血栓素(TX)、白三烯(LT)、醛固酮(ALD)和心钠肽(ANP)水平。结果在治疗2 w末,观察组24 h尿量为(1864.9±206.5)ml,显著多于对照组【(1050.7±186.2)ml,t = 5.366,P = 0.000】;观察组腹水消退时间为(13.8±4.5)d,显著短于对照组【(20.3±8.0)d,t = 5.011,P = 0.000】;观察组MRA、IRA和SRA肾血管收缩期最大血流速度分别为(75.5±9.0)cm/s、(37.2±4.4)cm/s和(56.4±5.7)cm/s,显著快于对照组;观察组舒张期最低血流速度分别为[(25.7±3.6)cm/s、(16.3±3.1)cm/s和(14.9±2.7)cm/s,显著快于对照组;观察组血清LPS、TX、LT和ALD水平分别为(10.6±1.8)pg/ml、(95.2±14.5)pg/ml、(88.4±7.7)pg/ml和(189.6±12.4)pg/ml,均显著低于,而血清ANP水平为(347.1±60.4)ng/L,显著高于对照组【分别为(13.2±2.1)pg/ml、(104.5±18.7)pg/ml、(94.7±8.5)pg/ml、(198.7±15.8)pg/ml和(271.3±44.7)ng/L,P < 0.05】。结论采取腹水浓缩回输治疗失代偿期肝硬化患者近期消退腹水作用明显,可能与改善了肾血流量,调节了血管活性因子水平有关。

关键词: 失代偿期肝硬化, 腹水浓缩回输, 肾血管血流, 血管活性因子, 治疗 , ,

Abstract: Objective The aim of this study was to observe the efficacy of ascites concentration and reinfusion (ACR) in treatment of patients with decompensated liver cirrhosis (DLC). Methods 102 patients with DLC and asciteswere admitted to our hospital between May 2016 and May 2018, and were divided into observation (n=60) and control (n=40) groups. The patients in the control were treated with routinesupporting therapy, and those in the observation were treated with ACR at base of general therapy. The maximum systolic and minimum diastolic blood flow velocities of main renal aorta (MRA), interlobular renal artery (IRA) and segmental renal artery (SRA) were measured by sonography. Serum levels of lipopolysaccharide (LPS), thromboxane (TX) , leukotriene (LT) ,aldosterone(ALD)and atrial natriuretic peptide (ANP) were detected. Results At the end of two week treatment,the 24-hour urine volume in the observation group was (1864.9±206.5) ml, significantly greater than 【(1050.7±186.2) ml, P < 0.05】, and the ascites subsidence time in the observation group was (13.8±4.5)d, significantly shorter than【(20.3±8.0)d, t = 5.011,P = 0.000】 in the control; the maximal systolic blood flow velocities of MRA, IRA and SRA inthe observation group were (75.5±9.0)cm/s,(37.2±4.4)cm/s and (56.4±5.7)cm/s, significantly quicker than 【(71.4±8.5)cm/s,(35.2±3.9)cm/s and (52.3±5.0)cm/s, P < 0.05】 in the control group; the lowest diastolic blood flow velocities of MRA, IRA and SRA were (25.7±3.6)cm/s,(16.3±3.1)cm/s and (14.9±2.7)cm/s,much quicker than 【(22.3±3.7)cm/s,(14.2±2.6)cm/s and (12.0±2.6)cm/s, P< 0.05】 in the control group; serum LPS, TX, LT and ALD levels in the observation were(10.6±1.8)pg/ml, (95.2±14.5)pg/ml, (88.4±7.7)pg/ml and (189.6±12.4)pg/ml, significantly lower than, while serum ANP level was (347.1±60.4)ng/L, much higher than in the control 【(13.2±2.1)pg/ml, (104.5±18.7)pg/ml, (94.7±8.5)pg/ml, (198.7±15.8)pg/ml and (271.3±44.7)ng/L, P<0.05】. Conclusion The ACR therapy for cirrhotic patients with ascites is Efficacious, which might be related to the improved renal blood flow and modulation of renal vasoactive factors.

Key words: Liver cirrhosis, Ascites concentration and reinfusion, Renal vasoactive factors, Renal blood flow, Therapy

贺连栋, 曹淑琴, 韩灿, 陈有玺. 腹水浓缩回输治疗失代偿期肝硬化患者肾血流和血清血管活性因子水平的变化[J]. 实用肝脏病杂志, 2020, 23(5): 707-710.

He Liandong, Cao Shuqing, Han Can, et al.. Efficacy of ascites concentration and reinfusion in treatment of patients with decompensated liver cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(5): 707-710.

参考文献

[1] Bossen L , Krag A , Vilstrup H , et al. Nonselectiveβ-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology, 2016, 63(6):1968-1976.
[2] Kathpalia P , Bhatia A , Robertazzi S , et al. Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites. Int Med J, 2015, 45(10):1026-1031.
[3] Neijenhuis M, Gevers, Tom J G, et al. Development and validation of a patient-reported outcome measurement for symptom assessment in cirrhotic ascites. Am J Gastroenterol,2018, 113(4):567-575.
[4] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31.
[5] Matei D , Pasca S , David A , et al. Hepatic hydrothorax in patients with cirrhosis and ascites – its prevalence and association with other cirrhosis complications. J Hepatol, 2017, 66(1):S135-S138.
[6] Franziska L , Reinhard M, Johannes W , et al. Predictive value of liver and spleen stiffness in advanced alcoholic cirrhosis with refractory ascites. Z Gastroenterol,2018,56(06):561-568.
[7] Kumada H , Okanoue T , Onji M , et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.Hepatol Res, 2010, 40(1):1-7.
[8] Cabibbo G , Petta S , Barbara M , et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.J Hepatol, 2017,67(1):65-71.
[9] 杨蕊旭,范建高.欧洲失代偿期肝硬化并发症管理指南简介.实用肝脏病杂志,2018, 21(4):12-17.
[10] 王淑珍,丁惠国.肝硬化顽固性腹水新的治疗模式及理念.中华肝脏病杂志,2017, 25(4):249-253.
[11] Uduwerella G , Chandrapala J , Vasiljevic T . Preconcentration of yoghurt base by ultrafiltration for reduction in acid whey generation during Greek yoghurt manufacturing.Int J Dairy Technol,2017,71(1):1-10.
[12] Marlicz W , Wunsch E , Mydlowska M , et al. The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis. J Pol Physiol Soc, 2016, 67(6):867-871.
[13] Suciu M , Gruia A T , Nica D V , et al. Data on expression of lipoxygenases-5 and -12 in the normal and acetaminophen-damaged liver. Data Brief, 2016, 7(8):1199-1203.
[14] Rhodes ER,Huff EM,Jones JL, et al.The evaluation of hollow-fiber ultrafiltration and celite concentration of enteroviruses, adenoviruses and bacteriophage from different water matrices. J Virol Methods, 2016,10(228):31-38.
[15] Ding L , Zhang W , Ould-Dris A , et al. Concentration ofmilk proteins for producing cheese using a shear-enhanced ultrafiltration technique. Ind Eng Chem Res, 2016,55(42):11130-11138.
[16] Togami S , Hori S , Kamio M , et al. Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis.Eur J Gynaecol Oncol, 2014, 35(3):301-303.
[17] Yamada Y , Harada M , Yamaguchi A , et al. Technicalperformance and clinical effectiveness of drop type with adjustable concentrator-cell free and concentrated ascites reinfusion therapy. Artif Organs, 2017,41(12):1135-1144.
[18] 张桢烨, 钱玲玲,郑杰, 等. 肾素血管紧张素醛固酮系统对大电导钙激活钾离子通道影响的研究进展.中华心血管病杂志, 2018, 46(3):239-242.
[19] Wang D , Gladysheva I P , Fan T H M , et al. Atrialnatriuretic peptide affects cardiac remodeling, function, heart failure, and survival in a mouse model of dilated cardiomyopathy. Hypertension, 2014, 63(3):514-519.
[20] Lee NCW, Carella MA, Papa S,et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. Front Cell Dev Biol, 2018,6:138.